on March 21, 2005
Published online before print March 21, 2005, doi: 10.1161/01.CIR.0000159356.42064.48
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 12, 2004
From the Departments of Internal Medicine (B.I.G., J.P.L., U.S., H.W.), Clinical Pharmacology (A.B.), and Anesthesiology and Intensive Care (E.S.), St Olavs Hospital HF, Trondheim University Hospital, and Departments of Laboratory Medicine, Children’s and Women’s Health (I.N.) and Cancer Research and Molecular Medicine (B.I.G., K.T., J.P.L., R.F., I.B., U.S., H.W.), Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. * To whom correspondence should be addressed. E-mail: bjorn.gustafsson{at}medisin.ntnu.no.
Background--The purpose of this study was to investigate whether rats dosed with serotonin develop changes similar to those seen in human carcinoid heart disease. Methods and Results--Ten Sprague-Dawley rats were given serotonin injections subcutaneously once daily for 3 months; controls were given saline. A long-lasting hyperserotoninemia with a >10-fold increase in both platelet-poor plasma and dialysate from the femoral muscles appeared. The animals developed clinical signs such as flushing and loose stools. After 3 months, 6 of 10 rats given serotonin had pathological echocardiographs. Two animals had a combination of aortic and pulmonary valve insufficiency, 1 had isolated aortic valve insufficiency, and 3 had isolated pulmonary valve insufficiency. Histopathological examination revealed shortened and thickened aortic cusps and carcinoidlike plaques characterized by a collection of myofibroblasts within an extracellular matrix of collagen ground substance. Immunostaining for Ki-67 demonstrated an increased number of proliferating subendocardial cells. In the control group, no pathological changes were seen. With the use of reverse-transcription polymerase chain reaction, normal rat aortic cusps were shown to express mRNA for serotonin receptors 5-HT1A, 5-HT2A, and 5-HT2B and the serotonin transporter 5-HTT. Conclusions--For the first time, long-term serotonin administration was performed in rats. Morphological and echocardiographic changes similar to those seen in human carcinoid heart disease developed. This study demonstrates that serotonin most likely is involved in the pathogenesis of carcinoid heart disease.
Revised on November 12, 2004
Accepted on November 15, 2004
Long-Term Serotonin Administration Induces Heart Valve Disease in Rats
Björn I. Gustafsson MD*,
Key words: carcinoid heart disease • receptors • serotonin • valves
This article has been cited by other articles:
 |
|
 |
|
  R. A. Pena-Silva, J. D. Miller, Y. Chu, and D. D. Heistad Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1354 - H1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connolly, M. A. Bakay, J. T. Fulmer, R. C. Gorman, J. H. Gorman III, M. A. Oyama, and R. J. Levy Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin Am. J. Pathol., September 1, 2009; 175(3): 988 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Villeneuve, A. Caudrillier, C. Ordener, N. Pizzinat, A. Parini, and J. Mialet-Perez Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H821 - H828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp Role of echocardiography in toxic heart valvulopathy Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Droogmans, B. Roosens, B. Cosyns, C. Degaillier, S. Hernot, C. Weytjens, C. Garbar, V. Caveliers, M. Pipeleers-Marichal, P. R. Franken, et al. Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1940 - H1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. El-Hamamsy, K. Balachandran, M. H. Yacoub, L. M. Stevens, P. Sarathchandra, P. M. Taylor, A. P. Yoganathan, and A. H. Chester Endothelium-Dependent Regulation of the Mechanical Properties of Aortic Valve Cusps J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Watts The love of a lifetime: 5-HT in the cardiovascular system Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R252 - R256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Elangbam REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns Vet. Pathol., January 1, 2009; 46(1): 10 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Rasmussen, S. H. Poulsen, E. Dupont, K. Ostergaard, G. Safikhany, and H. Egeblad Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking Eur J Echocardiogr, November 1, 2008; 9(6): 803 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Modlin, S. F. Moss, D. C. Chung, R. T. Jensen, and E. Snyderwine Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors J Natl Cancer Inst, September 17, 2008; 100(18): 1282 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Diaz, W. Ni, J. Thompson, A. King, G. D. Fink, and S. W. Watts 5-Hydroxytryptamine Lowers Blood Pressure in Normotensive and Hypertensive Rats J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 1031 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Weir, M. Obreztchikova, and Z. Hong Fenfluramine: riddle or Rosetta stone? Eur. Respir. J., February 1, 2008; 31(2): 232 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Donnelly Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases Toxicol Pathol, February 1, 2008; 36(2): 204 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zolkowska, M. H. Baumann, and R. B. Rothman Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 791 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Bernheim, H. M. Connolly, J. Rubin, J. E. Moller, C. G. Scott, D. M. Nagorney, and P. A. Pellikka Role of Hepatic Resection for Patients With Carcinoid Heart Disease Mayo Clin. Proc., February 1, 2008; 83(2): 143 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhattacharyya, J. Davar, G. Dreyfus, and M. E. Caplin Carcinoid Heart Disease Circulation, December 11, 2007; 116(24): 2860 - 2865. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Droogmans, P. R. Franken, C. Garbar, C. Weytjens, B. Cosyns, T. Lahoutte, V. Caveliers, M. Pipeleers-Marichal, A. Bossuyt, D. Schoors, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology Eur. Heart J., September 1, 2007; 28(17): 2156 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Levy Serotonin Transporter Mechanisms and Cardiac Disease Circulation, January 3, 2006; 113(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
|
|
A. Mekontso-Dessap, F. Brouri, O. Pascal, P. Lechat, N. Hanoun, L. Lanfumey, I. Seif, N. Benhaiem-Sigaux, M. Kirsch, M. Hamon, et al. Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice Circulation, January 3, 2006; 113(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Hoit Echocardiographic Characterization of the Cardiovascular Phenotype in Rodent Models Toxicol Pathol, January 1, 2006; 34(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|